MX2013015259A - Un ensayo de respuesta inmunitaria mediada por celulas con sensibilidad potenciada. - Google Patents
Un ensayo de respuesta inmunitaria mediada por celulas con sensibilidad potenciada.Info
- Publication number
- MX2013015259A MX2013015259A MX2013015259A MX2013015259A MX2013015259A MX 2013015259 A MX2013015259 A MX 2013015259A MX 2013015259 A MX2013015259 A MX 2013015259A MX 2013015259 A MX2013015259 A MX 2013015259A MX 2013015259 A MX2013015259 A MX 2013015259A
- Authority
- MX
- Mexico
- Prior art keywords
- enhanced sensitivity
- immune response
- assay
- cell mediated
- mediated immune
- Prior art date
Links
- 238000003556 assay Methods 0.000 title abstract 4
- 230000035945 sensitivity Effects 0.000 title abstract 2
- 230000021633 leukocyte mediated immunity Effects 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 125000000539 amino acid group Chemical group 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 230000001404 mediated effect Effects 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 230000001900 immune effect Effects 0.000 abstract 1
- 230000010354 integration Effects 0.000 abstract 1
- 210000004698 lymphocyte Anatomy 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Health & Medical Sciences (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Esta descripción se refiere generalmente al campo de ensayos de diagnósticos basados en inmunológicos que incluyen un ensayo para medir la inmunosensibilidad mediadas por células. La presente descripción enseña el diagnóstico de la exposición de un sujeto a un antígeno basado en la inmunosensibilidad mediada por células con sensibilidad potenciada. Los linfocitos de un sujeto se ponen en contacto con por lo menos un primer conjunto de péptidos que comprenden por lo menos un péptido de 7 a 14 residuos de aminoácidos en longitud y un segundo conjunto que comprende por lo menos un péptido de 16 residuos de aminoácidos o mayor y se detecte la presencia o elevación de una molécula inmunitaria. Un ensayo contemplado en la presente es capaz de integración en la arquitectura de patología estándar para proporcionar un sistema de reporte de diagnóstico y para facilitar el punto de manejo ce la atención clínica.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161502811P | 2011-06-29 | 2011-06-29 | |
PCT/AU2012/000756 WO2013000021A1 (en) | 2011-06-29 | 2012-06-27 | A cell mediated immune response assay with enhanced sensitivity |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2013015259A true MX2013015259A (es) | 2014-04-16 |
MX357717B MX357717B (es) | 2018-07-20 |
Family
ID=47423289
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013015259A MX357717B (es) | 2011-06-29 | 2012-06-27 | Un ensayo de respuesta inmunitaria mediada por células con sensibilidad potenciada. |
Country Status (20)
Country | Link |
---|---|
US (2) | US9983207B2 (es) |
EP (2) | EP3351936A1 (es) |
JP (1) | JP6150177B2 (es) |
KR (1) | KR102022513B1 (es) |
CN (3) | CN108593936B (es) |
AU (4) | AU2012276280B2 (es) |
BR (1) | BR112013033520B1 (es) |
CA (1) | CA2840484C (es) |
CY (1) | CY1120633T1 (es) |
DK (1) | DK2726883T4 (es) |
ES (1) | ES2673697T5 (es) |
HU (1) | HUE037801T2 (es) |
LT (1) | LT2726883T (es) |
MX (1) | MX357717B (es) |
PT (1) | PT2726883T (es) |
RU (2) | RU2018107763A (es) |
SI (1) | SI2726883T2 (es) |
TR (1) | TR201808740T4 (es) |
WO (1) | WO2013000021A1 (es) |
ZA (1) | ZA201309155B (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2367561B1 (en) | 2008-11-30 | 2015-05-20 | Immusant, Inc. | Compositions and methods for treatment of celiac disease |
JP2012167952A (ja) * | 2011-02-10 | 2012-09-06 | Central Automotive Products Ltd | アルコール検知器 |
SI2726883T2 (sl) | 2011-06-29 | 2022-09-30 | Cellestis Limited | Test celično posredovanega imunskega odziva s povečano občutljivostjo |
JP6123282B2 (ja) * | 2012-12-20 | 2017-05-10 | 富士電機株式会社 | プログラマブルコントローラおよび電源切断対処方法 |
HUE038527T2 (hu) * | 2012-12-28 | 2018-10-29 | Cellestis Ltd | Sejtek által közvetített immunválasz |
JP2014229116A (ja) * | 2013-05-23 | 2014-12-08 | 富士電機株式会社 | プログラマブルコントローラおよび電源切断対処方法 |
CA2923822A1 (en) | 2013-09-10 | 2015-03-19 | Immusant, Inc. | Dosage of a gluten peptide composition |
AU2015323979A1 (en) | 2014-09-29 | 2017-05-18 | Immusant, Inc. | Use of HLA genetic status to assess or select treatment of celiac disease |
EP3210015A1 (en) * | 2014-10-23 | 2017-08-30 | Qiagen Sciences, LLC | Peptide composition and uses thereof |
EP3302457A2 (en) | 2015-06-08 | 2018-04-11 | Lophius Biosciences GmbH | Composition for determination of cell-mediated immune responsiveness |
GB201605210D0 (en) * | 2016-03-29 | 2016-05-11 | Oxford Immunotec Ltd | Assay |
AU2019253924A1 (en) * | 2018-04-19 | 2020-11-26 | StickyCell Pty Ltd | Leukocyte recruitment in infectious disease |
EP3775894B1 (en) * | 2018-05-11 | 2024-04-24 | OBI Pharma, Inc. | Method for predicting human immune response |
JP6796737B1 (ja) * | 2020-06-02 | 2020-12-09 | 振武 曽 | 多項目自動血球計数装置 |
EP4179328A2 (en) * | 2020-07-10 | 2023-05-17 | Covid Diagnostics Ltd. | Compositions, methods, and systems for detecting immune response |
CN114062665B (zh) * | 2020-08-05 | 2023-04-28 | 菲鹏生物股份有限公司 | 示踪粒子标记目标分子及其制备方法和应用 |
CN113238060B (zh) * | 2021-05-08 | 2022-10-11 | 迈克生物股份有限公司 | 用于预测或诊断心肌炎的试剂盒 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4018653A (en) | 1971-10-29 | 1977-04-19 | U.S. Packaging Corporation | Instrument for the detection of Neisseria gonorrhoeae without culture |
US4016043A (en) | 1975-09-04 | 1977-04-05 | Akzona Incorporated | Enzymatic immunological method for the determination of antigens and antibodies |
US4424279A (en) | 1982-08-12 | 1984-01-03 | Quidel | Rapid plunger immunoassay method and apparatus |
US20020131976A1 (en) † | 1998-12-23 | 2002-09-19 | Ajit Lalvani | Tuberculosis vaccine |
DE60130435T2 (de) * | 2000-02-24 | 2009-07-23 | Invitrogen Corp., Carlsbad | Gleichzeitige stimulation und konzentration von zellen |
AUPQ689900A0 (en) | 2000-04-14 | 2000-05-11 | Commonwealth Scientific And Industrial Research Organisation | Bubble acoustics |
DK1432439T3 (da) * | 2001-10-02 | 2006-04-03 | Mologen Ag | Middel til forbedring af immunsvaret |
WO2004004758A1 (en) * | 2002-07-05 | 2004-01-15 | Lipoxen Technologies Limited | Method to enhance an immune response of nucleic acid vaccination |
ITRM20040091A1 (it) † | 2004-02-19 | 2004-05-19 | Istituto Naz Per Le Malattie | Test immunologico rapido per la diagnosi ed il monitoraggio dell'infezione tubercolare. |
EP1751181B1 (en) | 2004-06-02 | 2012-08-15 | AdAlta Pty Ltd | BINDING MOIETIES BASED ON SHARK IgNAR DOMAINS |
AU2008229636B2 (en) * | 2007-03-16 | 2014-08-14 | QIAGEN Australia Holding Pty. Ltd. | A cell-mediated immune response assay and kits therefor |
BRPI0817052A2 (pt) * | 2007-08-30 | 2015-03-24 | Genentech Inc | Métodos para o tratamento de uma doença auto-imune e distúrbio, método de inibição de atividade biológica, método para aumentar uma atividade biológica, método para a detecção de uma doença auto-imune, população de células t cd4+, método para isolar uma população de células t cd4+, kit, uso de um modulador crtam, modulador crtam e anticorpo. |
EP2106803A1 (en) | 2008-04-04 | 2009-10-07 | Fondazione Centro San Raffaele del Monte Tabor | Method to design and uses of overlapping peptides for monitoring T-cell responses in HIV patients |
NZ588406A (en) * | 2008-04-23 | 2012-05-25 | Healthlinx Ltd | An assay comprising determining levels of biomarkers including ca125 and at least one selected from agr-2, midkine and crp for detecting a gynecological condition |
CA2731854C (en) * | 2008-07-25 | 2020-06-30 | Cellestis Limited | Measurement of cell-mediated immune response reactivity to detect or monitor a disease or condition |
US9459253B2 (en) * | 2009-12-23 | 2016-10-04 | Cellestis Limited | Assay for measuring cell-mediated immunoresponsiveness |
SI2726883T2 (sl) | 2011-06-29 | 2022-09-30 | Cellestis Limited | Test celično posredovanega imunskega odziva s povečano občutljivostjo |
-
2012
- 2012-06-27 SI SI201231303T patent/SI2726883T2/sl unknown
- 2012-06-27 WO PCT/AU2012/000756 patent/WO2013000021A1/en active Application Filing
- 2012-06-27 CN CN201810440565.XA patent/CN108593936B/zh active Active
- 2012-06-27 LT LTEP12804281.9T patent/LT2726883T/lt unknown
- 2012-06-27 BR BR112013033520-3A patent/BR112013033520B1/pt active IP Right Grant
- 2012-06-27 CN CN201280031730.7A patent/CN103703375B/zh active Active
- 2012-06-27 KR KR1020147002072A patent/KR102022513B1/ko active IP Right Grant
- 2012-06-27 MX MX2013015259A patent/MX357717B/es active IP Right Grant
- 2012-06-27 RU RU2018107763A patent/RU2018107763A/ru unknown
- 2012-06-27 TR TR2018/08740T patent/TR201808740T4/tr unknown
- 2012-06-27 HU HUE12804281A patent/HUE037801T2/hu unknown
- 2012-06-27 EP EP18158828.6A patent/EP3351936A1/en active Pending
- 2012-06-27 EP EP12804281.9A patent/EP2726883B2/en active Active
- 2012-06-27 DK DK12804281.9T patent/DK2726883T4/da active
- 2012-06-27 AU AU2012276280A patent/AU2012276280B2/en active Active
- 2012-06-27 CN CN202210619543.6A patent/CN115144594A/zh active Pending
- 2012-06-27 US US14/129,517 patent/US9983207B2/en active Active
- 2012-06-27 CA CA2840484A patent/CA2840484C/en active Active
- 2012-06-27 RU RU2013154967A patent/RU2647468C2/ru active
- 2012-06-27 JP JP2014517329A patent/JP6150177B2/ja active Active
- 2012-06-27 ES ES12804281T patent/ES2673697T5/es active Active
- 2012-06-27 PT PT128042819T patent/PT2726883T/pt unknown
-
2013
- 2013-12-05 ZA ZA2013/09155A patent/ZA201309155B/en unknown
-
2017
- 2017-08-09 AU AU2017213471A patent/AU2017213471A1/en not_active Abandoned
-
2018
- 2018-04-25 US US15/962,988 patent/US20190101536A1/en not_active Abandoned
- 2018-05-16 CY CY181100505T patent/CY1120633T1/el unknown
-
2019
- 2019-08-30 AU AU2019222928A patent/AU2019222928B2/en active Active
-
2022
- 2022-04-28 AU AU2022202799A patent/AU2022202799A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2013015259A (es) | Un ensayo de respuesta inmunitaria mediada por celulas con sensibilidad potenciada. | |
Braun et al. | Presence of SARS-CoV-2-reactive T cells in COVID-19 patients and healthy donors | |
EP3546939A3 (en) | An assay for measuring cell-mediated immunoresponsiveness | |
Yin et al. | HLA-DM constrains epitope selection in the human CD4 T cell response to vaccinia virus by favoring the presentation of peptides with longer HLA-DM–mediated half-lives | |
Yang et al. | CD4+ T cells recognize unique and conserved 2009 H1N1 influenza hemagglutinin epitopes after natural infection and vaccination | |
Chang et al. | Analysis of total immunoglobulin E and specific immunoglobulin E of 3,721 patients with allergic disease | |
BR112015005308A2 (pt) | dispositivo de aquisição de imagem por ultrassonografia tridimensional e sistema de formação de imagem por ultrassonografia | |
RU2013139476A (ru) | Способ обнаружения проницаемости кишечного, а также гематоэнцефалического барьера и материалы для соответствующих тестов | |
Gambichler et al. | Occurrence of circulating anti-bullous pemphigoid antibodies in patients with lichen sclerosus. | |
WO2013164763A3 (en) | A biological complex specific for alzheimer's disease detection in vitro and use thereof | |
FR2896588B1 (fr) | Methode de diagnostic in vitro de reponse immunitaire autoimmune par detection d'anticorps diriges contre l'antigene pentraxine 3. | |
MA46814B2 (fr) | Anticorps anti-lag3 radiomarqués pour imagerie immuno-pet | |
JP2016509609A5 (es) | ||
RU2015130287A (ru) | Адаптация вируса гриппа н5 к человеку | |
US20180318386A1 (en) | Peptides and methods of treating endometriosis using the same | |
WO2011109112A3 (en) | Method of detecting tau protein and tau fragments in serum | |
Hirokawa et al. | Expression of genes encoding inflammasome sensor subunits in the duodenal and colonic mucosae of dogs with chronic enteropathy | |
Muris et al. | Palladium allergy prevalence is underestimated because of an inadequate test allergen. | |
Jagtap et al. | sMAdCAM: iL-6 ratio influences disease progression and anti-viral responses in SARS-CoV-2 infection | |
Moreews et al. | Superantigenic TCR Vbeta 21.3 signature in Multisystem Inflammatory Syndrome in Children | |
WO2006086760A3 (en) | Diagnostic measurement of disease | |
Dias et al. | The challenge of treating orphan disease | |
Serrão et al. | Annular lichen planus in association with Crohn disease | |
Jagtap et al. | sMAdCAM: IL-6 (sMIL Index): A novel signature associated with COVID-19 disease progression and development of anti-SARS-CoV-2 antibodies | |
AV | Drug-induced subacute cutaneous lupus erythematosus: evidence for differences from its idiopathic counterpart |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |